Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

NCT02248571 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer Recurrent
HER2/Neu-negative Carcinoma of Breast
Hormone Receptor Positive Malignant Neoplasm of Breast

Interventions

DRUG: Bevacizumab
DRUG: Capecitabine
DRUG: Everolimus
DRUG: Exemestane
OTHER: Patient questionaires

Sponsor

iOMEDICO AG

Collaborators

[object Object]
[object Object]